A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Resected non small cell lung cancer.
- Who it may be relevant to
- Registry conditions: Non-small Cell Lung Cancer Stage IIIA. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.
Detailed description
This study will use data from an already available cohort of patients enrolled in the Resting study (a project funded by TRANSCAN in 2018) as a training set and data from a new concurrent cohort as validation set.
Interventions
- Other Resected non small cell lung cancer
plasma sample, tissue sample and computed tomography scan images
Primary outcome measures
- Algorithm for disease free survival [Time frame: 18 months]
Eligibility criteria
Inclusion criteria
- Patient with an early stage of non small cell lung cancer
- Indication of surgical resection
- Patient able to understand and give his consent
- Patient affiliated to the health insurance
Exclusion criteria
- Patient with another cancer in the last 5 years
- Patient with an allergy to the contrast medium
- Patient under legal protection
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Julien MAZIERES — Toulouse
Identifiers
NCT: NCT05732974 · RC31/21/0519